The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment

Anna McLean; Steven Kao; David Barnes; Keith Wong; Richard A Scolyer; Wendy A. Cooper; Maija R.J. Kohonen‐Corish

doi:10.1016/j.lungcan.2022.01.011

Back

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Corrigendum2022

Corrigendum to “The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment” [Lung Cancer 165C (2022) 124–132]

Anna McLean, Steven Kao, David Barnes, Keith Wong, Richard A Scolyer, Wendy A. Cooper, Maija R.J. Kohonen‐Corish

Article2018

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)

Anna Tsiara, Michalis Liontos, Μαρία Καπαρέλου, Roubini Zakopoulou, Aristotelis Bamias, Meletios A Dimopoulos

Article1997

Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.

Vassilis Georgoulias, C. Kourousis, N. Androulakis, S. Kakolyris, Meletios A Dimopoulos, Demosthenes Bouros, C. Papadimitriou, Kostas Hatzakis, P. Heras, K. Kalbakis, Thanos Kotsakis, N. Vardakis, N. Meramveliotakis, Dora Hatzidaki

Article2023

The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures

Katarína Balážová, Hans Clevers, Antonella Fm Dost

Article1997

Second line treatment of non-small cell lung cancer with paclitaxel and gemcitabine

Stylianos Kakolyris, C. Kourousis, N. Androulakis, Meletios A Dimopoulos, E. Papadakis, S. Tzannes, Thanos Kotsakis, N. Vardakis, N. Merambeliotakis, C. Kalbakis, D. Xatzidaki, V. Georgoulias